Huiting Wei
Impact in
-
- PARP inhibition in cancer therapy
-
- Phagocytosis and Immune Regulation
- Immune cells in cancer
- interferon and immune responses
Papers in
-
- Cell death mechanisms and regulation 2
- Bioactive Natural Diterpenoids Research 1
- Phytochemical compounds biological activities 1
- Oncology 4
- Inflammatory Biomarkers in Disease Prognosis 1
- Co-authors
- Junying Yuan (2 shared papers)Zhi Yao (4 shared papers)Xingyan Li (1 shared paper)Ying Li (1 shared paper)Huibing Wang (1 shared paper)Shao‐Cong Sun (1 shared paper)Kezhou Zhu (1 shared paper)Huyan Meng (1 shared paper)
- Journals
- Journal of drug targeting (1 paper)The Journal of Pathology (1 paper)Cell Death and Disease (1 paper)Oncotarget (1 paper)Frontiers in Immunology (1 paper)
- Partner nations
- ChinaUnited StatesPoland
In The Last Decade
Huiting Wei
12 papers receiving 518 citations
Peers
Comparison fields: 5 of 72
- Oncology 211
- Immunology 148
- Molecular Biology 330
- Cancer Research 60
- Endocrinology 15
Countries citing papers authored by Huiting Wei
This map shows the geographic impact of Huiting Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huiting Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huiting Wei more than expected).
Fields of papers citing papers by Huiting Wei
This network shows the impact of papers produced by Huiting Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huiting Wei. The network helps show where Huiting Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Huiting Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 228 | |
| 2 | 2017 | 94 | |
| 3 | 2017 | 72 | |
| 4 | 2018 | 41 | |
| 5 | 2017 | 39 | |
| 6 | 2022 | 15 | |
| 7 | 2013 | 13 | |
| 8 | 2016 | 13 | |
| 9 | 2022 | 3 | |
| 10 | 2020 | 3 | |
| 11 | 2025 | 2 | |
| 12 | 2024 | 1 |
About Huiting Wei
Huiting Wei is a scholar working on Molecular Biology, Oncology, Surgery, Neurology and Endocrinology, having authored 12 papers that have together received 524 indexed citations. Recurring topics across this work include Escherichia coli research studies (2 papers), Cell death mechanisms and regulation (2 papers), Bioactive Natural Diterpenoids Research (1 paper), Phagocytosis and Immune Regulation (1 paper), Phytochemical compounds biological activities (1 paper), Inflammatory Biomarkers in Disease Prognosis (1 paper), Tissue Engineering and Regenerative Medicine (1 paper) and Bladder and Urothelial Cancer Treatments (1 paper). The work is most often cited by research in Oncology (211 citations), Immunology (148 citations), Molecular Biology (330 citations), Cancer Research (60 citations) and Endocrinology (15 citations). Huiting Wei has collaborated with scholars based in China, United States and Poland. Frequent co-authors include Junying Yuan, Zhi Yao, Xingyan Li, Ying Li, Huibing Wang, Shao‐Cong Sun, Kezhou Zhu, Huyan Meng, Adnan K. Mookhtiar and Kangyun Dong. Their work appears in journals such as Journal of drug targeting, The Journal of Pathology, Cell Death and Disease, Oncotarget and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.